MDS 病例中单体 7 或 7q 缺失、三体 8、20q 缺失和 Y 染色体缺失时克隆大小的临床影响。
Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome.
机构信息
Department of Pathology, Hospital del Mar, GRETNHE, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
出版信息
Leuk Res. 2011 Jun;35(6):834-6. doi: 10.1016/j.leukres.2011.01.003. Epub 2011 Jan 26.
The clone size has been postulated as a prognostic factor in myelodysplastic syndromes (MDS), though it has not been studied systematically. We tested its impact (<100% vs. 100%) in a population of 216 MDS with chromosome 7 abnormalities (-7/7q-) (n=84), trisomy 8 (n=99), 20q deletion (n=28) and loss of Y chromosome (n=26). Focusing on the survival the bad prognosis of -7/7q- was independent of the clone size (9.3 vs. 5.0 months, P=0.188, not significant) but trisomy 8 cases with 100% aberrant metaphases did reveal a worse prognosis (13.9 vs. 5.9 months, P=0.003).
克隆大小已被推测为骨髓增生异常综合征 (MDS) 的预后因素，但尚未系统研究。我们在一个有 216 例染色体 7 异常（-7/7q-）（n=84）、三体 8（n=99）、20q 缺失（n=28）和 Y 染色体丢失（n=26）的 MDS 患者人群中测试了其影响（<100%对 100%）。关注生存情况，-7/7q-的不良预后与克隆大小无关（9.3 对 5.0 个月，P=0.188，无显著性），但三体 8 中 100%异常中期的病例预后更差（13.9 对 5.9 个月，P=0.003）。
Zotero 插件